All In Biotech

Drug Trial Radar · NCT00027300

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jan 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

900

Actual

Start

Nov 2001

Primary completion

Nov 2004

Study completion Jan 2005

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
Elan Pharmaceuticals
First posted
Dec 3, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

  • NatalizumabDrug

    Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.

  • PlaceboDrug

    Placebo, IV infusion, every 4 weeks, for up to 116 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary objectives of this study are to determine whether natalizumab, when compared with placebo, is effective in reducing the rate of clinical relapses at 1 year and, in slowing the progression of disability at 2 years.Time frame: 1 year and 2 years

Locations

53 sites in 8 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona

  • East Bay Region Associates in Neurology

    Berkeley, California

  • UC Davis School of Medicine, Department of Neurology

    Davis, California

  • Yale University School of Medicine, Department of Neurology

    New Haven, Connecticut

  • University of Miami School of Medicine, Department of Neurology

    Miami, Florida

  • University of Kansas Medical Center, Department of Neurology

    Kansas City, Kansas

  • Michigan Institute for Neurological Disorders

    Farmington Hills, Michigan

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Gimbel MS Center

    Teaneck, New Jersey

  • CMRRC

    Albuquerque, New Mexico

  • Oregon Health Sciences University, Department of Neurology

    Portland, Oregon

  • Lehigh Valley Hospital, Neurosciences Research

    Allentown, Pennsylvania

  • Texas Neurology

    Dallas, Texas

  • University of Washington MS Research Center

    Seattle, Washington

  • Algemeen Ziekenhuis St. Jan

    Bruges, Belgium

  • LUC- University Centre

    Diepenbeek, Belgium

  • National MS Centrum

    Melsbroek, Belgium

  • MS Research Unit, Center for Clinical Research

    Halifax, Canada

  • Family Medical Centre

    Ottawa, Canada

  • Vancouver Hospital and Health Sciences Center UBC Pavilion, MS Clinical Research Group

    Vancouver, British Columbia, Canada

  • Health Services Centre

    Winnipeg, Manitoba, Canada

  • Kingston General Hospital, Neurology

    Kingston, Ontario, Canada

  • University Hospital

    London, Ontario, Canada

  • Sunnybrook and Women's College and Health Science Centre

    Toronto, Ontario, Canada

  • University of Toronto, MS Clinic, St. Michael's Hospital

    Toronto, Ontario, Canada

  • CHVO Hull Hospital

    Québec, Quebec, Canada

  • Faculty Hospital Brno Bohunice

    Brno, Czechia

  • Faculty Hospital St. Anne

    Brno, Czechia

  • Faculty Hospital of Hradec Kralove

    Hradec Králové, Czechia

  • Faculty Hospital Olomouc

    Olomouc, Czechia

  • Faculty Hospital Of Ostrava Poruba

    Ostrava, Czechia

  • Hospital Pardubice - Department of Neurology

    Pardubice, Czechia

  • Faculty Hospital Plzen - Clinic of Neurology

    Pilsen, Czechia

  • General Teaching Hospital - Neurological Department

    Prague, Czechia

  • Faculty Hospital Motol - Neurological Clinic

    Prague, Czechia

  • Hopital de la Timone, Service de Neurologie

    Marseille, France

  • CHRU - Hopital de Pontchaillou, Service de Neurologie

    Rennes, France

  • St. Josef-Hospital, Neurologische Klinik der Ruhruniversitat Bochum

    Bochurn, Germany

  • Klinika Neurologii

    Bydgoszcz, Germany

  • Academisch Ziekenhuis VU

    Amsterdam, Netherlands

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.